• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
【24h】

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib

机译：ALK重新排列的非小细胞肺癌的临床特征和结果，致力于屈服

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Crizotinib is associated with a favorable survival benefit in patients with ALK-positive non-small cell lung cancer (NSCLC); however, a subset of patients harboring ALK rearrangement shows a poor response. We collected the clinical features and survival outcomes of 28 primary-resistant responders (PRR) with progression-free survival (PFS) of 24?months PFS (control). Primary resistance was observed in 6.5% of the patients. The median PFS of the PRR and LTR groups was 1.2?months (95% confidence interval [CI] 0.70-1.73) and 47.0?months (95% CI 34.39-59.64), respectively. A better Eastern Cooperative Oncology Group performance status score was significantly associated with longer PFS (odds ratio 0.06, 95% CI 0.01-0.33; P?=?0.001). The median overall survival (OS) of the PRR group was 8.4?months (95% CI 3.47-13.42) and crizotinib as first-line treatment was an independent predictive factor for survival outcome (P?=?0.005). Patients administered ALK-tyrosine kinase inhibitors after crizotinib progression had significantly longer survival than the PRR group treated with best supportive care (P?=?0.007), but no significant difference was found between ALK-tyrosine kinase inhibitor treatment and single chemotherapy (P?=?0.944). Patients with primary resistance to crizotinib displayed unfavorable survival outcomes and the underlying mechanism cannot be identified in clinical features. Nevertheless, next-generation ALK inhibitors and chemotherapy after crizotinib progression could confer a therapeutic and survival benefit in this population. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：Crizotinib与ALK阳性非小细胞肺癌（NSCLC）患者有利的生存益处有关;然而，含有ALK重排的患者的父亲显示出差的反应。我们收集了28个初级抗响应者（PRR）的临床特征和生存结果，其进展存活（PFS）为24个月PFS（控制）。在6.5％的患者中观察到初级抗性。 PRR和LTR组的中位数PFS为1.2？月份（95％置信区间[CI] 0.70-1.73）和47.0个月（95％CI 34.39-59.64）。更好的东方合作肿瘤组性能状态分数与较长的PFS显着相关（0.06，95％CI 0.01-0.33; p？= 0.001）。 PRR组的中位数存活率（OS）为8.4？月份（95％CI 3.47-13.42）和Crizotinib，作为一线治疗是生存结果的独立预测因素（P？= 0.005）。患者患有Alk-tyrosine激酶抑制剂后，在Crizotinib进展后的存活率明显较长，比用最佳的支持护理治疗（P？= 0.007），但在Alk酪氨酸激酶抑制剂处理和单一化疗之间没有发现显着差异（P？ = 0.944）。患有初级抵抗的患者患有不利的存活结果，并且不能在临床特征中鉴定下潜在机制。然而，下一代ALK抑制剂和化疗在CRIZOTINIB进展后可以赋予该人群治疗和生存效果。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号